Quarterly Revenue Growth
Q1 2026 sales of $440 million, up 0.5% on a reported basis and up 1.3% on an organic basis versus the prior year.
Strength in Core Product Lines (C&V and CRM&N)
Cardio & Vascular sales of $262 million, up 1% in Q1 and up 13% on a trailing 4-quarter basis to $1.110 billion driven by EP, acquisitions and Neurovascular demand. Cardiac Rhythm Management & Neuromodulation sales of $168 million, up 5% in Q1; trailing 4-quarter CRM&N sales up 2% to $677 million.
Earnings Per Share Benefited from Lower Interest and Buybacks
Adjusted EPS of $1.20 in Q1; benefited from $4 million lower interest expense (added approximately $0.10 per share) and share repurchases (completed $50 million in Q4 2025 and $50 million in Q1 2026, reducing weighted average shares ~2% and adding ~$0.02 to EPS).
Targeted Cost Actions and Margin Recovery Plan
Company is implementing additional near-term cost reduction actions (designed not to compromise customer service or long-term growth) and expects Q2 adjusted operating income margin to improve 80–140 basis points sequentially with margins improving throughout 2026.
Balance Sheet Discipline and Leverage in Target Range
Net total debt of $1.264 billion (up $74 million QoQ) yields a net total debt leverage of 3.2x trailing 4-quarter adjusted EBITDA, which is inside the company’s strategic target range of 2.5x–3.5x.
Strategic Review Initiated to Maximize Shareholder Value
Board initiated a strategic review in response to heightened interest; review may consider a range of alternatives while management reiterates confidence in the stand‑alone strategy and long-term objectives.
Long-Term Market Position and Pipeline
Management reiterates confidence in attractive med-tech end markets (target market growth 4%–6%), a robust new product pipeline and the expectation to return to organic sales growth ~200 basis points above market in 2027.
Cash Deployment and Capital Plan
Continued share repurchases (totaling ~$100 million across Q4 2025 and Q1 2026) and guidance for 2026 CapEx of $95–105 million (~5%–6% of sales), with expected free cash flow of $85–105 million for the year.